Thalidomide, also known as Thalomid, is currently approved in Canada for treating those with multiple myeloma. It is only accessible through a controlled distribution program called RevAid, to which the prescribing physician must be registered. This drug acts by suppressing the immune system, thereby reducing inflammation, and can also prevent new blood vessel formation. It is currently being investigated for use in other cancers, inflammatory conditions such as rheumatoid arthritis, lupus, HIV related mouth sores/ulcers and is approved by the FDA for use in leprosy. It was first prescribed in the late 1950’s early 1960’s to treat insomnia and morning sickness in pregnant women however by 1962 it was pulled from the market as it was discovered that it caused severe birth defects. It resurface in 1999 when the FDA approved it for leprosy and then in 2006 for multiple myeloma.

Health Canada, in collaboration with Celgene Inc, have recently issued two health alerts for Thalidomide. The first, May 1st, announced the potential risk of arterial blood clot formation and death due to these clots causing heart attack or stroke, especially in the first five months of use. The second alert, May 22nd, announced that Thalidomide has the potential to cause secondary cancers, specifically the blood cancers acute myeloid leukemia and myelodysplastic syndrome.

If you’re currently taking thalidomide or have taken it in the past and have concerns make sure to speak to your healthcare provider.